Aanjaneya Lifecare acquires Apex Drugs for Rs 250 crore

03 Feb 2012 Evaluate

Drug maker, Aanjaneya Lifecare has acquired Hyderabad-based Apex Drugs and Intermediates (ADIL). The acquisition was valued at Rs 250 crore with debt of Rs 185 crore and equity dilution of Rs 65 crore. The Mumbai-based company has acquired ADIL’s assets, businesses, clients, licensees, employees and has merged both the companies' operations.

The company will leverage the strong relations of ADIL developed in Asia, Europe, UAE and Latin America for exports. The acquisition will help Aanjaneya Lifecare to widen its product portfolio in various therapeutic segments including AIDS, Diabetes and central nervous system.

Aanjaneya Lifecare is a leading research based integrated pharmaceutical company with established research, manufacturing and marketing capabilities.  It is R&D focused, has a multi product portfolio with state of the art manufacturing facilities, and is set to become a marketing conglomerate across the globe.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×